XXBI price
About XXBI
SPDR Series Trust - State Street SPDR S&P Biotech ETF is an exchange traded fund launched by State Street Global Advisors, Inc. The fund is managed by SSGA Funds Management, Inc. It invests in public equity markets of the United States. It invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the S&P Biotechnology Select Industry Index, by using representative sampling technique. SPDR Series Trust - State Street SPDR S&P Biotech ETF was formed on January 31, 2006 and is domiciled in the United States.
- Stock ticker
- XBI
- Company
- State Street SPDR S&P Biotech ETF
- Industry
- Financial Services
- Category
- US
- Stock split / reverse split
- 13
- Launch date
- 6 Feb 2006
- Listed exchange
- AMEX
Dividends
XXBI performance
XXBI price today is $140.18, marking a -2.73% over the past 24 hours. On OKX, today’s XXBI trading volume reached --, worth over --.
The current XXBI to USD conversion rate is $140.18 per XXBI.
More to explore
FAQ
XXBI is trading at $140.18, -2.73% over the last 24 hours. Track live moves on the price chart at the top of this page.
The XXBI stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. XXBI is currently trading at $140.18, -2.73% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on XXBI price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Financial Services sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. XXBI's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from XXBI; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against XXBI's historical range and other companies in the Financial Services sector.
State Street SPDR S&P Biotech ETF's market cap is currently 7.33B USD. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.




















